

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

TCC-Pan2

RRID:CVCL_3178

Type: Cell Line

Proper Citation

RRID:CVCL_3178

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3178

Proper Citation: RRID:CVCL_3178

Description: Cell line TCC-Pan2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:30747829](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:32782605](#)

Comments: Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TCC-Pan2

Synonyms: TCC-PAN2, TCCPAN2

Cross References: EFO:EFO_0006764, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:451, BioSample:SAMN03472903, BioSample:SAMN10988353, cancercellines:CVCL_3178, Cell_Model_Passport:SIDM01464, DepMap:ACH-000502, EGA:EGAS00001000610, GEO:GSM887690, GEO:GSM888782, GEO:GSM1588616, GEO:GSM1588628, IARC_TP53:28256, JCRB:JCRB1072, JCRB:JCRB1921, LiGeA:CCLE_741, PharmacDB:TCCPAN2_1569_2019, Progenetix:CVCL_3178, Wikidata:Q54971862

ID: CVCL_3178

Record Creation Time: 20220427T221621+0000

Record Last Update: 20260830T000100+0000

Ratings and Alerts

No rating or validation information has been found for TCC-Pan2.

No alerts have been found for TCC-Pan2.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer research, 86(8), 1868.

Drizyte-Miller K, et al. (2025) Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. Cancer research, 85(18), 3540.

Santana-Codina N, et al. (2022) NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron-Sulfur Cluster Proteins. Cancer discovery, 12(9), 2180.

Venkatanarayan A, et al. (2022) CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell reports, 38(6), 110351.